Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Jun 19, 2007

Sanofi-aventis and Bristol-Myers Squibb Prevail in U.S. Plavix® Patent Litigation
Jun 15, 2007

FDA approves new route of administration for rapid-acting Apidra® providing an additional treatment option for hospitalized diabetes patients with high blood sugar levels
Jun 14, 2007

Sanofi Pasteur Awarded Contract to Retrofit Influenza Vaccine Facility

Sanofi pasteur continues to join with the U.S. government in enhancing the nation’s pandemic preparedness to protect public health
Jun 13, 2007

FDA Advisory Committee did not recommend approval of rimonabant (Zimulti®) for use in obese and overweight patients with associated risks factors
Jun 4, 2007

THE ELOXATIN®-BASED REGIMEN (FOLFOX4) SIGNIFICANTLY IMPROVED PROGRESSION FREE SURVIVAL WHEN GIVEN BEFORE AND AFTER SURGERY IN PATIENTS WITH RESECTABLE LIVER METASTASES FROM COLORECTAL CANCER
Jun 4, 2007

ELOXATIN® (oxaliplatin injection)-BASED CHEMOTHERAPY SETS NEW TREATMENT BENCHMARK IN PATIENTS WITH METASTATIC COLORECTAL CANCER
Jun 4, 2007

UPDATED STUDY RESULTS REINFORCE SURVIVAL BENEFIT OF TAXOTERE® (DOCETAXEL) FOR MEN WITH ADVANCED, HORMONE-RESISTANT PROSTATE CANCER
Jun 3, 2007

“My child matters” program one-year report shows measurable improvement in cancer care for children in developing and newly industrialized countries
Jun 3, 2007

FOLFOX4 (ELOXATIN®-based chemotherapy) AFTER SURGERY IMPROVES OVERALL SURVIVAL IN PATIENTS WITH EARLY (STAGE III) COLON CANCER
Jun 3, 2007

S-1, A NOVEL ORAL FLUOROPYRIMIDINE, WHEN COMBINED WITH CISPLATIN, DEMONSTRATES SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL OF ADVANCED GASTRIC CANCER PATIENTS OVER S-1 ALONE
Jun 3, 2007

OXFORD BIOMEDICA AND SANOFI-AVENTIS REPORT NEW TROVAX® PHASE II TRIAL RESULTS IN RENAL CANCER
Jun 2, 2007

RESULTS OF VEGF TRAP (AFLIBERCEPT) HIGHLIGHTED AT ASCO 2007 ANNUAL MEETING
May 29, 2007

FDA approves XYZAL® (levocetirizine dihydrochloride) tablets for the relief of seasonal and year round allergies, and chronic hives
May 29, 2007

Data to be presented at ASCO 2007 highlights sanofi-aventis commitment to cancer care and research
May 18, 2007

FDA Approves LOVENOX® (enoxaparin sodium injection) for the most severe type of heart attack
May 15, 2007

Sanofi-aventis calls for an effective policy against drug counterfeiting
May 8, 2007

Sopranos Star Aida Turturro speaks out to encourage fellow diabetes patients to take control
May 3, 2007

Full-year guidance raised on good 2007 first-quarter results
Apr 30, 2007

FDA Approves Lantus SoloStar® - A new prefilled disposable insulin pen for use with LANTUS® in people with Type 1 and Type 2 diabetes
Apr 20, 2007

The Lancet publishes PREVAIL study results showing LOVENOX® superiority over unfractionated heparin for reducing the risk of venous thromboembolism in patients with acute ischemic stroke
Apr 17, 2007

FDA Licenses First U.S. Vaccine for Humans Against Avian Influenza

sanofi pasteur receives first U.S. license for a vaccine against avian influenza in humans marking an important milestone in pandemic preparedness
Apr 17, 2007

The U.S. Food and Drug Administration Approves New ACTONEL Dose to Treat and Prevent Postmenopausal Osteoporosis
Mar 26, 2007

Rimonabant USA: Update
Mar 25, 2007

Data Shows That Omission of Venous Thromboembolism (VTE) Prophylaxis in Hospitalized Medical Patients Is Frequent and Leads to Higher Risk of Deep-Vein Thrombosis (DVT)
Mar 16, 2007

Award-winning actress and singer Lainie Kazan travels across the country urging Americans to understand the signs, symptoms and risk factors for Deep-Vein Thrombosis (DVT)
Mar 13, 2007

ALLEGRA® (fexofenadine hydrochloride) Oral Supsension now available to help manage seasonal allergy symptoms in children
Mar 12, 2007

Sanofi-aventis Debuts AgingWithBeauty.com
Mar 6, 2007

Actor Cheryl Hines is tired of counting sheep to sleep…and is painting them instead
Mar 1, 2007

New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available
Feb 27, 2007

Sanofi Pasteur Statement
Feb 12, 2007

Rimonabant USA: Update
Feb 12, 2007

Sanofi-aventis announces update to US Prescribing Information for KETEK® (telithromycin)
Feb 7, 2007

FDA grants priority review to LOVENOX® (enoxaparin sodium injection) supplemental new drug application (sNDA) for acute heart attack
Feb 6, 2007

Tim Rothwell appointed Chairman of Sanofi-aventis Group U.S. pharmaceutical activities; Greg Irace named President and CEO of U.S. pharmaceutical operations
Feb 1, 2007

Sanofi-aventis applauds new national standards for prophylaxis of venous thromboembolism in surgical patients
Jan 25, 2007

FDA Advisory Committee Recommends Licensure of New Pediatric Combination Vaccine

If approved, Pentacel vaccine would be the first pediatric combination vaccine in the U.S. to immunize against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (Hib)
Jan 19, 2007

S-1 oral anticancer agent improves patients’ survival in adjuvant gastric cancer trial versus surgery alone
Dec 20, 2006

Sanofi Pasteur Influenza Vaccine Production Tops 170 Million Doses in 2006

Record production capabilities strengthen sanofi pasteur’s global leadership in the fight against seasonal influenza and place the company at the forefront of pandemic readiness
Dec 15, 2006

Sanofi-aventis statement regarding U.S. FDA joint advisory committee recommendation for KETEK® (telithromycin)
Dec 12, 2006

New study shows LOVENOX® (enoxaparin sodium injection) is more effective than unfractionated heparin (UFH) for lowering the risk of venous thromboembolism (VTE) in patients with acute ischemic stroke

The PREVAIL study showed that in acute ischemic stroke patients treated with Lovenox, the risk of having a VTE was lowered by a significant 43% with no statistically significant increase in clinically important bleedings when compared to UFH
Dec 8, 2006

Rimonabant update in the United States
Dec 5, 2006

New data shows Rimonabant benefited patients with type 2 diabetes by improving blood sugar control, reducing weight and acting on other cardiometabolic risk factors

First Rimonabant Trial with HbA1c as a Primary Endpoint
Nov 27, 2006

Sanofi Pasteur Completes Shipment of 50 Million Doses of Influenza Vaccine

Sanofi pasteur able to produce additional vaccine to meet customer demand
Nov 20, 2006

Sanofi Pasteur Signs Contract with U.S. Government for Stockpile of New Type of H5N1 Pre-Pandemic Vaccine

New pre-pandemic vaccine will provide additional level of preparedness
Oct 31, 2006

First 9th months of 2006: Sales growth of 2.6% on a comparable basis - Adjusted EPS growth of 15.0%, or 7.5% excluding selected items

Sales Growth of 2.6% on a Comparable Basis(1)
Oct 30, 2006

New study shows SCULPTRA® (injectable poly-l-lactic acid), a unique class of injectable for cosmetic use, provides 13 month results

Comparative Clinical Trial Results Announced for the Treatment of Nasolabial Folds at the 2006 American Society of Dermatologic Surgery (ASDS) Annual Meeting
Oct 18, 2006

TAXOTERE® receives U.S. FDA approval for the treatment of patients with head and neck cancer

Taxotere(R)-based regimen demonstrates a significantly longer progression free survival and 29 percent reduction in the risk of mortality in patients with inoperable locally advanced head and neck cancer
Oct 18, 2006

FDA approves ALLEGRA® (fexofenadine hydrochloride) oral suspension for treatment of seasonal allergy symptoms and chronic idiopathic urticaria

New formulation provides non-impairing symptom relief for pediatric populations
Oct 12, 2006

Sanofi Pasteur Remains on Track to Deliver 50 Million Doses of Influenza Vaccine to U.S. Market for 2006-2007 Season

As communicated by CDC, majority of supply will be available in October and November; sanofi pasteur shipped one-third of influenza vaccine planned for 2006-2007 season
Sep 29, 2006

Sanofi Pasteur and the Pediatric Dengue Vaccine Initiative Partner Against Dengue Fever

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.